‘I am being vegetarian now': Priyanka Chopra Jonas shares her go-to meals when in India and the US; here's why they are good for you
'Dinner always starts with soup. I love having a nice, warm soup. Then, having the same that I have for lunch. It is super tasty, and healthy. Then I have various other things, I love dal, I love bhindi. I love aloo gobhi. I am being vegetarian now. Then, I always need a dahi, I love having raita and achaar is very important. Salad's very important,' she told the host.
'Now when I'm in the US, I am usually not a sandwich person. I don't like sandwiches, but I always like roast fish with veggies. I love a good, fresh salad,' she added.
Many like to begin their meals with a bowl of scrumptious and filling soup. But, turns out, apart from being an appetiser, beginning a meal with soup also has several health benefits!
Delhi-based nutritionist Pooja Bohra shared some benefits to starting your meals with a warm vegetable soup:
*It is a high source of fluids.
*Soups are healthy and nutritious.
*Soup preserves its nutritional value.
*They are full of healthy fibres.
*Soups are rich in taste.
*It is a powerhouse of antioxidants.
*Soups fill up the volume in your stomach.
*It leaves less room for more calorie-dense food item
Kanikka Malhotra, consultant dietician and certified diabetes educator, tells indianexpress.com, 'Regular consumption of curd after lunch can significantly alter gut microbiota composition due to its probiotic content, primarily Lactobacillus and Bifidobacterium strains. These live cultures enhance beneficial bacterial populations, improving microbial diversity and suppressing harmful bacteria.
According to her, the lactic acid bacteria in curd strengthens gut barrier function, reduces inflammation, and promotes short-chain fatty acid production, which supports colon health. Curd's probiotics also improve nutrient absorption, reduce bloating, and may lower the risk of inflammatory bowel conditions by balancing gut flora.
However, pairing curd with spicy dishes may not be suitable for all. The contrast in temperature between cold curd and hot spices could lead to digestive discomfort, particularly in individuals with sensitive stomachs. 'There is no evidence suggesting that the combination is harmful. However, some individuals with sensitive stomachs might experience discomfort due to the contrasting temperatures,' she added.
Sushma PS, chief dietitian, Jindal Naturecure Institute said that salads are alkaline foods that serve as a preventive measure against acid accumulation within the body, supporting gentle detoxification processes. 'The consumption of a salad promotes gastrointestinal health by incorporating ingredients characterised by low acidity levels and rich fibre, vitamin, and mineral content, which are essential for digestive well-being,' said Sushma.
DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Dr Reddy's Q1 result: Net profit up 2%, revenue hits record ₹8,545 crore
Hyderabad-based pharma major Dr Reddy's Laboratories (DRL) posted a consolidated net profit of ₹1,417 crore in the first quarter of financial year 2026 (Q1 FY26), a 2 per cent rise from ₹1,392 crore a year ago. The company clocked its highest-ever quarterly revenue at ₹8,545 crore, up 11 per cent year-on-year (Y-o-Y) from ₹7,672 crore. The increase in profit and revenue was attributed to new product launches and price hikes during the quarter. Sequentially, revenue was flat, with a marginal 0.4 per cent rise, while net profit declined by 11 per cent. G V Prasad, co-chairman and managing director, DRL, said: 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio.' Dr Reddy's is planning a major global rollout of semaglutide beginning in 2026, targeting 87 countries—including India, Brazil, Canada, and Turkey—subject to local patent expiries. In countries without active patents, launches will begin earlier. In India and Brazil, where the patent expires in March 2026, the company is targeting Day 1 launches. Erez Israeli, chief executive officer, DRL, said: 'The semaglutide launch is very important to us. It reflects our focus on business development, resource optimisation, and cost alignment for future growth. While there are execution risks, I'm confident we'll overcome them and continue our growth trajectory. Our pipeline includes 26 peptide-based GLP-1 products, expected to launch over the next decade.' Despite ongoing litigation with Novo Nordisk in India regarding the validity of the semaglutide patent, Dr Reddy's does not anticipate any delays or disruptions to its commercialisation plans. The company expects significant topline contribution from semaglutide, citing growing global demand for GLP-1 therapies in diabetes and weight management. Priced lower than Novo's offering (₹17,000 per month), Dr Reddy's plans to use its integrated manufacturing to enhance accessibility. Semaglutide is the first of 26 GLP-1 peptide-based drugs the company plans to launch globally over the next decade, with timing based on regional IP clearance. Dr Reddy's has guided for capital expenditure of approximately ₹2,700 crore in FY26, with major investments toward expanding peptide and biosimilar capacity in line with product-specific requirements. Segment Performance Global Generics: Revenue stood at ₹8,060 crore, up 10 per cent Y-o-Y, supported by new launches and stable volumes. North America: Revenue was ₹3,412 crore, down 11 per cent Y-o-Y due to price erosion in key products like Lenalidomide. The company launched five new products and filed one ANDA with the USFDA. As of June 2025, 73 filings are pending, including 70 ANDAs (43 Para IVs, 22 with potential First-to-File status) and three NDAs. Europe: Revenue surged 142 per cent Y-o-Y to ₹1,274 crore, driven by the NRT acquisition. The NRT business contributed ₹670 crore. Germany reported ₹320 crore (up 13 per cent), the UK ₹170 crore (up 10 per cent), and the rest of Europe ₹120 crore (up 30 per cent). Growth was led by new launches and forex gains, partly offset by price erosion. Thirteen new products were launched. Emerging Markets: Revenue rose 18 per cent Y-o-Y to ₹1,404 crore. Russia contributed ₹710 crore (up 28 per cent), the Commonwealth of Independent States and Romania ₹200 crore (up 2 per cent), and the rest of world territories ₹500 crore (up 13 per cent). A total of 26 new products were launched across these regions. Pharmaceutical Services and Active Ingredients: Revenue rose 7 per cent Y-o-Y to ₹818 crore, supported by new API launches, forex gains, and pharmaceutical services expansion. The company filed 12 Drug Master Files globally during the quarter. The results were announced post market hours. Dr Reddy's shares rose 0.58 per cent, closing at ₹1,247.50 apiece on the BSE.
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Natco Pharma to acquire 35.75% stake in Adcock Ingram for ₹2,000 cr
The proposed Rs 2,000 crore deal will give Natco Pharma a strategic foothold in South Africa, with transaction completion expected within four months subject to approvals Sanket Koul New Delhi In a bid to enter the African market, Natco Pharma on Wednesday announced that it has submitted a firm intention for a ZAR 4 billion (Rs 2,000 crore) cash offer to acquire a minority stake in South Africa-based drugmaker Adcock Ingram Holdings (AIHL). If approved, the Hyderabad-based company will hold a 35.75 per cent stake in Adcock Ingram by offering ZAR 75.00 ($4.271) per share to minority stakeholders. The deal gives Natco a gateway into South Africa, with AIHL holding a 10 per cent share of the private pharmaceutical market in the country. It is also the largest supplier of hospital and critical care products in South Africa. This transaction would consolidate Natco's existing 0.80 per cent stake, making it the second-largest shareholder in AIHL, behind the Bidvest Group, which holds the remaining 64.25 per cent. 'Post-transaction, Natco will consolidate 35.75 per cent of AIHL's net profits in Natco's financial results in accordance with its shareholding,' the company said in a regulatory filing. If the deal proceeds, Adcock Ingram will be delisted from the Johannesburg Stock Exchange (JSE) and will continue to operate as a private South African business. Rajeev Nannapaneni, chief executive officer and vice-chairman of Natco Pharma, said the proposed acquisition would help the company tap into new revenue streams and expand its presence in one of the largest and fastest-growing emerging markets. In return, AIHL is expected to leverage Natco's research and development capabilities, regulatory expertise, and global marketing network to support local leadership and expansion into new markets. 'AIHL will benefit from a partnership with a research-focused, innovative, and vertically integrated pharmaceutical company, and over time, South Africans will be beneficiaries of wider access to affordable medicines,' said Andrew Hall, chief executive officer, AIHL. Valued at an estimated ZAR 11 billion ($632 million), AIHL generated revenues of ZAR 9.6 billion ($536 million) for the financial year ending June 2024. Founded in 1890, the company operates across four segments—prescription, consumer, over-the-counter (OTC), and hospitals. It has a diverse product portfolio ranging from generic and branded formulations to critical-care hospital products, as well as consumer and home-care products. The announcement was made after market hours. On Wednesday, Natco Pharma's shares rose by 2.01 per cent, ending the day's trade at Rs 1,034.75 apiece on the Bombay Stock Exchange (BSE).
NDTV
an hour ago
- NDTV
Swiggy Rolls Out 'High Protein' Category On App To Promote Healthier Eating
Food delivery platform Swiggy has rolled out a new feature for users wanting to make healthier food choices. The company recently announced the launch of a dedicated 'High Protein' category on its app, which is now available across 30 cities in India. The initiative responds to the growing consumer demand for protein-rich meals. It is also designed "to make high protein food items and meals more visible, accessible, and integrated into everyday ordering behaviour," as per Swiggy. The new category already includes over 5 lakh dishes curated from more than 35,000 restaurant partners across cities like Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Kolkata, and Chandigarh, among others. Also Read: Swiggy Launches New Travel And Lifestyle App 'Crew': What It Does And How It Works How Does Swiggy's High-Protein Feature Work? Each dish listed under this category meets specific nutritional criteria: At least 15 grams of protein 700 kcal value or less A protein-to-calorie ratio of 10% or more "Proteins are an essential part of our daily intake," said Deepak Maloo, Vice President of Food Strategy, Customer Experience & New Initiatives at Swiggy. "With this launch, we aim to make high-protein dishes more accessible to our users, enabling better health and well-being. We will continue partnering with restaurants to expand these offerings." The launch of Swiggy's new feature follows a successful pilot phase where over 1.8 million users explored high-protein meals through the app. While metros like Bangalore, Mumbai, and Delhi led in orders, cities like Chandigarh also showed strong interest. This implies that there is indeed widespread demand for foods with high protein content. How To Use Swiggy's High-Protein Search Feature? The High Protein category is designed for easy discovery: Users can search terms like "Protein" or "Diet" on the Swiggy app to access the section. Dishes are organised by protein content, and users can filter by ingredients (specific protein sources) like paneer or soya. They can also browse protein-rich options within selected restaurants. Also Read: Swiggy User Ordered 200 Pizzas Worth Rs 45,000 In Single Order, Company Reveals Why The Focus On Protein? Several reports and studies have highlighted protein deficiencies in the Indian diet. In recent times, an increased interest in formal fitness and nutrition routines has also led to a heightened awareness of the importance of protein. Swiggy cited a report by ICRISAT, IFPRI, and CESS, which reveals that two-thirds of households in India's semi-arid tropics fall short of the recommended protein intake. It also mentioned an IMRB survey, which revealed that 73% of Indians are protein-deficient, with only 10% consuming sufficient protein in their daily diets. Swiggy's new category apparently aims to bridge this gap by making healthy food more visible and convenient. Advertisement For the latest food news, health tips and recipes, like us on Facebook or follow us on Twitter and YouTube. Tags: Swiggy Swiggy New Feature Swiggy High Protein Category High Protein Food News Show full article Comments
